1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. I-MAB Biopharma Acquires Bridge Health

M&A Deal Summary

I-MAB Biopharma Acquires Bridge Health

On July 17, 2025, I-MAB Biopharma acquired life science company Bridge Health for 3M USD

Acquisition Highlights
  • This is I-MAB Biopharma’s 1st transaction in the Life Science sector.
  • This is I-MAB Biopharma’s largest (disclosed) transaction.
  • This is I-MAB Biopharma’s 1st transaction in the United States.

M&A Deal Summary
Date 2025-07-17
Target Bridge Health
Sector Life Science
Buyer(s) I-MAB Biopharma
Deal Type Add-on Acquisition
Deal Value 3M USD

Target

Bridge Health

United States
Bridge Health provides I-Mab with the rights to bispecific and multi-specific applications (including bispecific and multi-specific antibodies and antibody drug conjugates (ADCs)), based on the Claudin 18.2 (CLDN18.2) parental antibody used in the Company’s CLDN18.2 x 4-1BB bispecific antibody, givastomig.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

I-MAB Biopharma

Rockville, Maryland, United States
Category Company
Founded 2014
Sector Life Science
Employees32
Revenue 1M USD (2023)
DESCRIPTION

I-MAB Biopharma is a global biotech company exclusively focused on developing innovative biologics of first-in-class or best-in-class potential in the therapeutic areas of immuno-oncology and autoimmune diseases. I-MAB Biopharma was founded in 2014 and is based in Rockville, Maryland.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2025 M&A 1 of 1
Size (of disclosed) 1 of 1
Mergr

Solution for

Product

Company

Legal